Keyphrases
Phase II Study
100%
Paclitaxel
100%
Advanced Carcinoma
100%
Group Studies
100%
Urothelium
100%
Eastern Cooperative Oncology Group
100%
Cisplatin
100%
Advanced Urothelial Cancer
75%
Confidence Interval
50%
Overall Response Rate
50%
Neurotoxicity
25%
Median Overall Survival
25%
Soft Tissue
25%
Phase II Trial
25%
Fever
25%
Active Agent
25%
Multi-institutional
25%
Objective Response
25%
Optimal Therapy
25%
Overall Survival Time
25%
Complete Clinical Response
25%
Institutional Context
25%
Visceral Tissues
25%
Granulocytopenia
25%
Advanced Urothelial Carcinoma
25%
Medicine and Dentistry
Carcinoma
100%
Paclitaxel
100%
Oncology
100%
Cisplatin
100%
Urothelium
100%
Urothelial Cancer
75%
Overall Survival
25%
Neurotoxicity
25%
Transitional Cell Carcinoma
25%
Phase II Trials
25%
Survival Time
25%
Granulocytopenia
25%
Side Effect
25%
Pharmacology, Toxicology and Pharmaceutical Science
Carcinoma
100%
Paclitaxel
100%
Cisplatin
100%
Malignant Neoplasm
75%
Overall Survival
25%
Neurotoxicity
25%
Phase II Trials
25%
Survival Time
25%
Transitional Cell Carcinoma
25%
Granulocytopenia
25%
Side Effect
25%